2017
The Cholangiocyte Adenosine‐IL-6 Axis Regulates Survival During Biliary Cirrhosis
Lavoie EG, Fausther M, Goree JR, Dranoff JA. The Cholangiocyte Adenosine‐IL-6 Axis Regulates Survival During Biliary Cirrhosis. Gene Expression 2017, 17: 327-340. PMID: 28893353, PMCID: PMC5885153, DOI: 10.3727/105221617x15042723767876.Peer-Reviewed Original ResearchConceptsBile duct ligationIL-6 releaseExogenous IL-6Common bile duct ligationBiliary cirrhosisIL-6Duct ligationInjury responseIL-6 mRNA expressionIL-6 upregulationIL-6 secretionA2B adenosine receptorsLiver cell typesA2BAR activationBile infarctsInflammatory cellsCirrhosisEpithelial responseH69 cellsIntracellular Ca2Adenosine receptorsExtracellular adenosineInduces releaseMRNA expressionRegulates Survival
2011
New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice
Fausther M, Dranoff JA. New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice. Journal Of Hepatology 2011, 55: 939-940. PMID: 21672564, PMCID: PMC3756144, DOI: 10.1016/j.jhep.2011.04.013.Peer-Reviewed Original ResearchHepatic stellate cellsHuman hepatic stellate cellsFarnesoid X receptorLiver fibrosisBiliary typeMouse modelCommon bile duct ligationNuclear bile acid receptorFXR protein expressionMouse hepatic stellate cellsFibrotic liver diseaseBile acid receptorBile duct ligationDifferent mouse modelsFXR knockout miceVitamin D receptorReceptor expression levelsDirect therapeutic targetsBiliary cirrhosisLiver diseaseHepatic fibrosisDuct ligationFXR expressionD receptorLiver expression
2007
Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS).
Dranoff JA, Kruglov EA, Abreu-Lanfranco O, Nguyen T, Arora G, Jain D. Prevention of liver fibrosis by the purinoceptor antagonist pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS). In Vivo 2007, 21: 957-65. PMID: 18210741.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsBile duct ligationLiver fibrosisDuct ligationPurinergic receptorsCommon bile duct ligationEffect of PPADSPurinergic receptor inhibitorsDevelopment of cirrhosisHSC proliferationEffective pharmacologic treatmentExperimental liver fibrosisAnnexin V flow cytometryEffect of suraminSirius red stainQuantitative RT-PCRPharmacologic treatmentReceptor inhibitorsPPADSStellate cellsLiver sectionsFibrosisBromodeoxyuridine uptakePurinoceptor activationExperimental animals